castle trial patient story
CAR‑T vs Conventional Therapy Chronic Disease Management Reality
In the CASTLE trial, 52% of patients receiving CD19 CAR-T achieved sustained remission at one year, outpacing the 24% remission rate seen with conventional biologics, showing that CAR-T can be a powerful alternative for chronic autoimmune disease. That headline figure comes from a small but groundbreaking basket study that tested